Navigation Links
Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology
Date:2/25/2009

10-Year Study Highlights Trabecular Metal Technology's Clinical Success Over Traditional Metal Implants

WARSAW, Ind., Feb. 25 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH), a leader in the orthopaedic industry, today announced that data from an independent 10-year Trabecular Metal(TM) Technology comparative clinical study demonstrates the osteoconductive properties of Zimmer's Trabecular Metal Technology. The study found bone-to-implant gap-filling and positive clinical outcomes up to 10 years after total hip arthroplasty (THA) using products made with Zimmer's Trabecular Metal Technology.

"This study reaffirms the positive clinical outcomes associated with using Trabecular Metal technology," commented Cheryl Blanchard, PhD, Zimmer's Senior Vice President, Research and Development, and Chief Scientific Officer. "Unique to Zimmer, Trabecular Metal technology allows for highly porous metal implants with flexibility very similar to cancellous bone."

The study, to be published in the Journal of Arthroplasty, followed 143 patients for up to 10 years post-THA. Findings indicate that Trabecular Metal monoblock implants result in a marked reduction in metallic and polyethylene debris and maximize the area available for bone in-growth. Further, the researchers observed a zero revision rate for aseptic loosening throughout the duration of the study and no incidence of implant migration and no radiographic evidence of gross polyethylene wear as measured digitally with (EBRA) Ein-Bild-Rontgen-Analyse.

"It is important to note that this study addresses concerns that have not been previously well characterized. It provides invaluable information about these mid-term outcomes after total hip arthroplasty and the potential adva
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
2. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
3. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
7. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
8. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
9. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
10. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
11. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Israele, February 27, 2015 ... sviluppo dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF ... sull,uomo-     ... di nuovo sistema per il monitoraggio cardiaco destinato ... annunciato oggi di aver concluso una raccolta di ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... 2015 An aggressive campaign to reduce the ... of infection with a dangerous drug-resistant bacteria at The ... difficile, or C.diff, is a bacterium that can cause ... colon. A recent article in the New England Journal ... the United States " asserts that ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... -- defined as men who down five or more drinks at ... one time, federal researchers reported Tuesday. Of the 17 percent ... 24 years old. But those 65 and older engage in the ...
... , INDIANAPOLIS -- The School of Science at Indiana ... Modeling and Computational Science, an interdisciplinary endeavor dedicated to ... the environment, and computer science. iM2CS,s parallel mission is ... the scientific issues with which they will be faced. ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers ... the drug Nexavar (sorafenib) in fighting a tough-to-treat form ... experimental drug known as ganetespib showed promise in laboratory ... studies were to be presented Tuesday at an American ...
... Island Hospital has found that collaborative ,behavioral management may ... users who are paroled. The findings have important implications ... U.S. community correctional population. The study is published in ... of print. In the U.S., over 700,000 inmates ...
... January issue of Health Affairs assesses real-world ... chronic disease that affects nearly 26 million Americans. ... systematically reviewed the published literature and analyzed 28 studies ... trial in real-world settings. Published in 2002, this major ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- The ... the risk of heart attack, a new review finds. ... trials involving Pradaxa that included more than 30,000 patients. This ... to tease out a pattern that might not show up ...
Cached Medicine News:Health News:One in Six Americans Binge Drink: CDC 2Health News:One in Six Americans Binge Drink: CDC 3Health News:Revealing causality 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 2Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 3Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3
... first instrument engineered to match the speed ... cycling system is based on heat transfer ... microcapillary tubes or thin walled micorcentrifuge tubes. ... of high velocity air results in nearly ...
... Excellent performance, small footprint, simple intuitive ... the Primus 25 the ideal personal cycler ... ,The flexiblock design and the self-adjusting heated ... or 13x 0.5ml vessels or a microplate ...
... day-to-day temperature cycling ,Unmatched ... ,30% reduction in cycling ... coolant-based cyclers ,4 programmable ... ,Options for oil-free and ...
... rapid, real-time thermal cycler used for identifying ... much of the testing process, and making ... the fastest, easiest to use, and most ... SmartCycler delivers highly accurate and consistent test ...
Medicine Products: